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Abstract
Background: Frontotemporal lobar degeneration (FTLD) represents a clinically, pathologically
and genetically heterogenous neurodegenerative disorder, often complicated by neurological signs
such as motor neuron-related limb weakness, spasticity and paralysis, parkinsonism and gait
disturbances. Linkage to chromosome 9p had been reported for pedigrees with the
neurodegenerative disorder, frontotemporal lobar degeneration (FTLD) and motor neuron
disease (MND). The objective in this study is to identify the genetic locus in a multi-generational
Australian family with FTLD-MND.
Methods: Clinical review and standard neuropathological analysis of brain sections from affected
pedigree members. Genome-wide scan using microsatellite markers and single nucleotide
polymorphism fine mapping. Examination of candidate genes by direct DNA sequencing.
Results: Neuropathological examination revealed cytoplasmic deposition of the TDP-43 protein
in three affected individuals. Moreover, we identify a family member with clinical Alzheimer's
disease, and FTLD-Ubiquitin neuropathology. Genetic linkage and haplotype analyses, defined a
critical region between markers D9S169 and D9S1845 on chromosome 9p21. Screening of all
candidate genes within this region did not reveal any novel genetic alterations that co-segregate
with disease haplotype, suggesting that one individual carrying a meiotic recombination may
represent a phenocopy. Re-analysis of linkage data using the new affection status revealed a
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maximal two-point LOD score of 3.24 and a multipoint LOD score of 3.41 at marker D9S1817.
This provides the highest reported LOD scores from a single FTLD-MND pedigree.
Conclusion:  Our reported increase in the minimal disease region should inform other
researchers that the chromosome 9 locus may be more telomeric than predicted by published
recombination boundaries. Moreover, the existence of a family member with clinical Alzheimer's
disease, and who shares the disease haplotype, highlights the possibility that late-onset AD patients
in the other linked pedigrees may be mis-classified as sporadic dementia cases.
Background
Frontotemporal lobar degeneration (FTLD) is the third
most common neurodegenerative cause of dementia after
Alzheimer's disease (AD) and dementia with Lewy bodies
(DLB). [1,2] It stems from the degeneration of neurons in
the superficial frontal cortex and anterior temporal lobes.
Typically, this results in several distinct clinical presenta-
tions characterised by changes in personality and behav-
iour, including a decline in manners and social skills
representative of frontotemporal dementia, as well as lan-
guage disorders of expression and comprehension,
known as progressive aphasia and semantic dementia,
respectively. [3] Contributing to the spectrum of clinical
phenotypes seen in FTLD is the co-occurrence of FTLD
with motor neurone disease (MND). [4] MND, also
referred to as amyotrophic lateral sclerosis (ALS) is charac-
terised by degeneration of upper and lower motor neu-
rons, leading to progressive muscle wasting, weakness and
spasticity which ultimately results in profound global
paralysis and death, usually due to respiratory failure.
FTLD is also a pathologically heterogeneous disorder and
can be categorised into cases without detectable inclu-
sions known as dementia lacking distinctive histopathol-
ogy (DLDH), cases with tau-positive pathology known as
tauopathies, and the most frequently recognised cases
have ubiquitin-positive, tau-negative inclusions (FTLD-
U). [5] The TAR DNA binding protein (TDP-43) is a
nuclear protein implicated in exon splicing and transcrip-
tion regulation, [6] and was recently identified as a major
protein component of the ubiquitin-immunoreactive
inclusions characteristic of sporadic and familial FTLD-U,
with and without MND, as well as in sporadic cases of
MND [7-9]. Recently, mutations in the TDP-43 (TARDBP)
gene have recently been reported in familial and sporadic
forms of MND. [10-14]
There is increasing evidence that FTLD and MND may rep-
resent two phenotypic variants resulting from a common
underlying genetic cause. This is supported by both the
presence of ubiquitin/TDP-43 pathology and also by
genetic loci on chromosome 9 in families with FTLD and
MND. Hosler et al. [15] identified a region on chromo-
some 9q21-22 from linkage data from 5 American FTLD-
MND families. Subsequently, both Vance et al. [16] and
Morita et al. [17] reported linkage to chromosome
9p13.2-21.3 in large FTLD-MND kindreds from Holland
and Scandinavia, respectively. Finally, three other families
were identified by Valdmanis et al. [18] with linkage to
the chromosome 9p locus. Yan et al. [19] have also pro-
vided a preliminary abstract report of significant linkage
in 15 FTLD-MND families. To date, only one gene, IFT74
has been postulated to be the causative gene of chromo-
some 9p-linked FTLD-MND. [20] However, only a single
family has been identified with a mutation in the IFT74
gene, suggesting genetic heterogeneity in this region.
Here, we report a large FTLD-MND family from Australia
with linkage to chromosome 9p21.1-q21.3 and TDP-43
positive pathology, further supporting the evidence for a
novel gene associated with this type of neurodegenerative
disorder.
Methods
Neuropathology
The brains of patients III:2, III:3 and III:12 and the spinal
cord of patient III:12 were obtained at the time of autopsy
with consent. Routine neuropathological assessment,
including immunohistochemical screening, was per-
formed and reviewed and standardised for the present
study. For all cases, retrospective review of standardised
immunoperoxidase slides using antibodies for tau
(MN1020, PIERCE, USA, diluted 1:10,000/cresyl violet),
ubiquitin (Z0458, DAKO, Denmark, diluted1:200/cresyl
violet), Aβ (gift from Professor Masters, University of Mel-
bourne, dilution 1:200/cresyl violet), and a-synuclein
(610787, Pharmigen, USA, diluted1:200/cresyl violet)
were undertaken as previously described. [21] TDP-43
protein was visualised following microwave antigen
retrieval (sections were boiled for 3 min in 0.2 M citrate
buffer, pH 6.0) using commercially available antibody
(BC001487, PTG, USA, diluted 1:500), peroxidase visual-
isation and counterstaining with 0.5% cresyl violet. To
determine final diagnoses all cases were screened using
current diagnostic criteria for AD, [22] dementia with
Lewy bodies, [23] FTLD, [9] MND, [24] and other neuro-
degenerative syndromes including corticobasal degenera-BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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tion, [25] progressive supranuclear palsy [26] and vascular
dementia. [27]
Genetic analyses
The study was approved by the University of New South
Wales Human Research Ethics Committee and complies
with the guidelines of the National Health and Medical
Research Council and the Helsinki Declaration. After writ-
ten informed consent was obtained, blood was collected
from 16 family members (seven of whom are affected)
and DNA extracted. A 10 cM genome-wide scan was per-
formed with microsatellite markers (ABI Prism Linkage
Mapping Set, version 2.5, MD-10). Parametric pair-wise
and multipoint LOD scores were calculated using the
MLINK and LINKMAP computer programs in the LINK-
AGE 5.2 package. Autosomal dominant inheritance was
assumed with age dependent penetrance, a phenocopy
rate of 0.005, a disease gene frequency of 0.001 and allele
frequencies derived from a normal Australian population.
[28] Seven liability classes were established based on ped-
igree data with 1% penetrance – age < 25 years, 8% –
between 26 and 34 years, 22% – between 35 and 44 years,
Pedigree diagram showing affection status and disease haplotype Figure 1
Pedigree diagram showing affection status and disease haplotype. Squares indicate males and circles females; filled arrow indi-
cates proband; black symbols show individuals clinically diagnosed with dementia, either AD or FTLD; diagonal stripes, individ-
uals diagnosed with MND; and combined black and diagonal stripes, individuals diagnosed with FTLD-MND. A diagonal line 
marks deceased subjects. Individual I:1, lived until his 80s, but was thought to have had some personality changes. Alleles in 
parentheses are inferred. 'X' indicates upper and lower recombination breakpoints that define the minimal disease haplotype.BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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46% – between 45 and 54 years, 71% – between 55 and
64 years, 91% – between 65 and 74 years, and 95% – age
> 75 years. Individuals were assigned a liability class based
on age-of-onset for affected cases and age at last consulta-
tion for asymptomatic cases. High-resolution fine map-
ping was performed using microsatellite markers with an
average heterozygosity of 0.79 and spaced no further apart
than 2 cM. Haplotypes were constructed using Merlin
(Version 2.01), double checked manually, and displayed
using HaploPainter V.029.5. [29] The haplotype of indi-
vidual III:5 was inferred from her spouse and offspring.
Mutation screen of candidate genes
Intronic polymerase chain reaction (PCR) primers were
designed to amplify each non-coding and coding exon, as
well as flanking intronic sequence of candidate genes
using the ExonPrimer program accessed using the UCSC
Genome Bioinformatics Site (primer sequences available
on request). PCR products amplified from genomic tem-
plates were sequenced using Big Dye Chemistry (Applied
Biosystems). Total RNAs were extracted from lymphoblas-
toid cell lines or frozen brain tissue for RT-PCR analysis. 1
μg of total RNA from each sample was reverse transcribed
using the Superscript III First Strand Synthesis System
(Invitrogen) and a oligodT primer (Invitrogen), followed
by PCR amplification using overlapping primers designed
to amplify the entire coding sequence of each candidate
gene (primer sequences available on request). Each over-
lapping pair was designed to avoid exon/intron bounda-
ries in order to detect splicing mutations. Each PCR
fragment was analysed for abnormalities by size fraction-
ation using agarose gel electrophoresis.
Results
Clinical and neuropathological examinations of affected 
members
We describe an Australian family of Anglo-Celtic origin
where eleven family members were affected with FTLD-
MND (Figure 1). Over three generations, five family mem-
bers (II:2, III:3, III:5, III:7, IV:1) presented with symptoms
consistent with the behavioural variant of FTLD (Figure
1). Another two family members (III:8, III:12) presented
with progressive bulbar and limb weakness consistent
with MND. Two family members presented with a combi-
nation of FTLD and MND features (II:5, III:6). One of the
other family member presented with early-onset demen-
tia (II:7) and had a son with MND (III:12). Of particular
interest is the eleventh affected family member. She pre-
sented with an amnestic picture and subsequently devel-
oped impairment in multiple cognitive domains
including visuospatial function, prompting a clinical
diagnosis of Alzheimer's disease (III:2). A full description
of her clinical presentation is available [see Additional file
1]. Of the eleven affected family members, two also devel-
oped paranoid delusions in their middle age, at the begin-
ning of their illnesses (III:6 and III:8). Average age of onset
was 53 years (range 43 to 68 years) with a mean disease
duration of 9 years (range 1 to 16 years), and mean age of
death of 61 years (range 46 to 75 years). An overall clinical
summary is provided in Table 1.
The location of the abnormal TDP-43-immunoreactive
protein deposits within layer II neurons of the frontal cor-
tex and hippocampal granule cells was identified as either
cytoplasmic, intranuclear or neuritic. These features were
used to classify the cases into histological subtypes accord-
ing Cairns et al. [5] Histopathological examination was
available for one family member with FTLD (III:3), find-
ing TDP-43 inclusions consistent with type 2 FTLD-U [9]
(Figure 2). Histopathological examination was available
for one family member with MND (III:12), again finding
TDP-43 inclusions in the dentate gyrus and anterior horn
cells (Figure 3). The individual (III:2) with clinical Alzhe-
imer's disease was found to have TDP-43 inclusions con-
sistent with type 2 FTLD-U (Figure 2), with co-existing
hippocampal sclerosis, as well as sufficient densities of
Table 1: Clinical summary
Individual Gender First symptoms Disease duration APOE genotype Clinical presentation
(years) (years) Psychosis FTD ALS Dementia*
II-2 M ~45 ~18 - + - -
III-3 M ~59 ~7 e3/e4 - + # --
III-5 F ~45 ~11 - + - -
III-7 F ~59 2 (alive) e3/e4 - + - -
IV-1 F 43 3 (alive) e3/e4 - + - -
II-5 F 63 1 - + + -
III-6 M 58 3 (alive) e4/e4 + + + -
III-8 F 46 4 e2/e4 + - + -
III-12 M 46 5 e4/e4 - - + # -
III-2 F 68 7 e3/e4 - - - + #
II-7 F 50 16 - - - +
* Refer to the text for details.
# Diagnosis confirmed by neuropathological examinationBMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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cortical plaques and tangles but insufficient CA1 hippoc-
ampal neuritic pathology to fulfil criteria for Alzheimer's
disease. Overall the severity of the FTLD-U histology for
III:2 was more severe than the Alzheimer's disease histol-
ogy. A detailed description of the clinical and pathological
presentation of affected pedigree members is presented in
Additional file 1.
Linkage of causative locus to chromosome 9
DNA from the proband (III:3), III:6, III:12 and III:1 was
subjected to DNA sequence analysis of the coding regions
and flanking intronic sequences for known dementia and
MND genes. No mutations were detected in the APP,
PSEN1, PSEN2, MAPT, PGRN, VCP, CHMP2B or the
IFT74 gene. No SOD1 or TDP-43 mutations were detected
in individuals III:8 and III:12.
A genome-wide linkage analysis was undertaken on 16
pedigree members, some of whom are not included in the
pedigree diagram for ethical reasons. Seven individuals
were classed as affected and one was classified as
unknown as she had psychosis, a possible FTLD prodro-
The neuropathology of patients III:2 and III:3 Figure 2
The neuropathology of patients III:2 and III:3. (A) Severe 
pyramidal neuronal loss from CA1 region Ammon's horn 
(III:2). (B) Temporal neocortex showing Aβ immunopositive 
plaques and cerebrovascular amyloidosis (III:2). Positive 
staining with ubiquitin (C-F) and TDP-43 (G-I) antibodies of 
neuronal cytoplasmic inclusions (NCI) in the granule cells of 
the dentate gyrus. Ubiquitin-positive neuronal cytoplasmic 
inclusions in III:2 (C, E and F) and in III:3 (D). TDP-43 posi-
tive neuronal cytoplasmic inclusions in III:2 (G and I) and III:3 
(H). Bar = 50 μm in A and B; 20 μm in C and G; 10 μm in D, 
E, F, H and I.
The neuropathology of case III:12 Figure 3
The neuropathology of case III:12. (A) C7 cervical cord 
showing symmetrical Wallerian degeneration of lateral corti-
cospinal tracts and anterior corticospinal tract. Note atrophy 
of anterior nerve roots in comparison to dorsal nerve roots. 
TDP-43 immunopositive skein-like (B) and punctate (C) 
cytoplasmic inclusions within anterior horn cells of the spinal 
cord. (D) Normal TDP-43 positive nuclear staining of the 
anterior horn cell. (E) Anterior horn cell showing Bunina 
bodies. (F) Spongiosis in layers 2 and 3 of parasagittal motor 
cortex. (G) Residual Betz cell in motor cortex. Bar = 10 μm 
in B, C, D, E and G; 20 μm in F.BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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mal feature. [16] Linkage analysis was carried out where a
single genetic locus was considered causal for all clinical
variants. Over the entire genome, the only region with a
two-point LOD score greater than the established cut-off
of 2.0 for suggestive linkage was located on chromosome
9. Marker D9S161 (9p21.3) gave a maximum LOD score
of 2.57. Three adjacent markers also had positive LOD
scores with the closest marker D9S1817 having a maxi-
mum LOD score of 0.99. The highest LOD score on a
chromosome other than 9 was 1.40 on 3p14.3. Otherwise
all other LOD scores were all consistently negative or non-
significant and were used to exclude other reported MND
linked loci, namely 2p13, 15q15-q22, 18q, 16q, and
20q13. These results indicate that the pedigree may be
linked to the chromosome 9p FTLD-MND locus. The can-
didate chromosome 9p region was subjected to high reso-
lution fine mapping with 8 additional markers (D9S259,
D9S169, D9S319, D9S1118, D9S304, D9S1845,
D9S1805, D9S163) surrounding D9S161 and D9S1817
and the data was re-analysed using MLINK. This resulted
in a significant two-point LOD score of 3.25 at marker
D9S319 (Table 2).
To further evaluate the reliability of the detected linkage,
and to determine recombination breakpoints, haplotypes
were constructed using Merlin (Figure 1). Recombination
breakpoints were defined by two affected individuals. The
telomeric boundary was marked by a recombination
event in individual II:2 between markers D9S169 and
D9S161, and has been inherited by all five affected off-
spring within the sibship (Figure 1). The centromeric
boundary was defined by a single cross-over in individual
III:8. However, using the microsatellite data, the exact
recombination breakpoint could not be determined as
markers D9S1118 and D9S304 are both homozygous for
the '2' allele and could not be excluded from the disease
haplotype. Therefore, we can only deduce with confidence
that the cross-over occurred between markers D9S304 and
D9S1845. All affected individuals share an identical hap-
lotype consisting of 4 consecutive markers (D9S161-
D9S319-D9S1118-D9S304) spanning a 9.6 cM region
corresponding to a physical distance of 5.9 Mb.
Fine mapping haplotype analysis and mutation screen of 
candidate genes
The 5.9Mb minimal disease region contains 14 known
genes as listed by the UCSC Bioinformatics page, consist-
ing of C9orf11 (ACR formation associated factor),
MOBKL2B, IFNK, c9orf72, LINGO2, ACO1, DDX58,
TOPORS, NDUFB6, TAF1L, APTX, DNAJA1, SMU1, and
B4GALT1 (Figure 4). The coding and non-coding exonic
sequence and flanking intronic regions of 11 of the initial
set of candidate genes (excluding TAF1L,  SMU1  and
B4GALT1) were screened by direct sequencing of PCR
products amplified from genomic template. Screening of
the candidate genes detected 42 polymorphisms, of which
six were considered novel, including two variants in
C9orf11 (IVS1 +33 GT insertion/deletion, IVS4 -44 G/A);
three in DDX58 (Arg71His CGT to CAT, IVS16 -23 C/A,
IVS16 + 11 G/A) and one in APTX (IVS6 -12 insertion/
deletion T). We considered the DDX58 amino acid change
to be a polymorphism as it was found in unaffected and
aged controls obtained from the Sydney Older Persons
Study cohort [30] with a frequency of 0.03.
The additional SNP genotypes from the mutation screen
were used to create an informative SNP haplotype and we
were able to further fine map the centromeric recombina-
tion breakpoint. SNP haplotypes from ACO1 and DDX58
(the two genes in closest proximity to the D9S304
marker) revealed that III:8 did not inherit the same alleles
of ACO1 and DDX58 as the other affected individuals.
This allowed us to place the meiotic cross-over to between
ACO1 and D9S304. As there are no known genes in the 60
kb region between ACO1 and D9S304, we have placed the
final position of the cross-over to between D9S1118 and
D9S304 (Figure 4). This haplotype analysis left 4 known
genes (IFNK, LINGO2, MOBKL2B, C9orf11), and a hypo-
thetical protein C9orf72 within the candidate region. No
mutations were detected in the exons (coding and non-
coding) or flanking intronic sequences of these five genes.
In addition, we analysed three of the five genes/transcripts
Table 2: Two-point LOD scores for chromosome 9p21.2-q22.32 
markers
III:8 Affected III:8 Unaffected
Marker Location θθ
(cM) 0.00 0.20 0.40 0.00 0.20 0.40
D9S259‡ 47.19 -2.1 -0.07 0.03 -2.21 -0.09 0.03
D9S169‡ 49.20 -0.54 0.53 0.08 -0.99 0.33 0.07
D9S161† 51.81 2.51 1.39 0.26 2.14 1.17 0.20
D9S319‡ 54.50 3.25 * 1.96 0.51 2.82 1.70 0.43
D9S1118‡ 58.26 1.08 0.59 0.13 1.05 0.57 0.43
D9S304‡ 58.26 0.34 0.14 0.01 0.31 0.11 0.00
D9S1845‡ 58.80 1.15 1.36 0.37 2.90 1.72 0.44
D9S1817† 59.34 1.47 1.55 0.43 3.24* 1.97 0.53
D9S1805‡ 59.34 0.75 1.2 0.26 2.46 1.41 0.30
D9S163‡ 59.87 1.34 0.53 0.04 0.94 0.31 0.00
D9S273† 65.79 1.03 1.36 0.37 2.77 1.62 0.40
D9S175† 70.33 0.50 1.01 0.28 2.26 1.40 0.36
D9S167† 83.41 -3.58 -0.30 0.01 -1.85 0.11 0.07
* Peak LOD Scores.
† ABI Prism Linkage Mapping Set markers.
‡ Marshfield Medical Research Foundation genetic framework 
markers.
All map distances are derived from the Marshfield Genetic Map 
except for marker D9S163 that was inferred from the Kong human 
genetic map. [33]BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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Fine mapping haplotype analysis using microsatellite and SNP markers to resolve the position of a meiotic recombination in  pedigree member III:8 Figure 4
Fine mapping haplotype analysis using microsatellite and SNP markers to resolve the position of a meiotic recombination in 
pedigree member III:8. Four SNPs from representative genes are indicated (rs10812616, rs10812615, rs17769294 and 
rs10122902 for C9orf11; rs2383768, rs13296489, rs1331870 and rs10968460 for LINGO2; rs2026739, rs3780473, 
rs10970975 and rs12985 for ACO1; rs10813831, Arg71His, rs17289927 and rs6476363 for DDX8). The informative SNP hap-
lotypes definitively place the recombination breakpoint between D9S1118 and D9S304. The black box indicates the portion of 
the disease haplotype which is not shared by pedigree member III:8. Transcript map indicating the relative positions of known 
genes and transcripts (open boxes) (not drawn to scale).BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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by RT-PCR of lymphoblastoid and brain cDNAs. The
exceptions were C9orf11, which had been annotated to
have testes specific expression (UCSC Bioinformatics
Site), and LINGO2, whose coding sequence is encom-
passed within a single large 3' exon (UCSC Bioinformatics
Site). No altered splicing or small-scale deletions in the
RT-PCR products from the transcripts of these candidate
genes were detected by size fractionation using agarose gel
electrophoresis (data not shown). The absence of any
mutations led us to conclude that III:8 may be a pheno-
copy and that the centromeric recombination breakpoint
defined by that individual (between D9S1118 and
D9S304) is not valid for defining the minimal disease
region.
Identification of an extended disease haplotype
We re-analysed our linkage data with the phenotype of
III:8 altered to an unaffected status using the same auto-
somal dominant inheritance model (Table 2). Again, only
a single locus achieved a significant two-point LOD score
of 3.24 at the marker D9S1817. The flanking markers,
D9S1845 and D9S1805 also achieved positive LOD scores
of 2.90 and 2.46, respectively (Table 2). A multi-point
LOD score of 3.41 was observed at marker D9S1817.
From the haplotype analysis (Figure 1), a new extended
disease haplotype was defined using the distal telomeric
meiotic cross-over between markers D9S175 and D9S167
(Figure 1) as identified in seven affected individuals II:2,
III:2, III:3, III:5, III:6, III:7 and IV:1. The disease haplotype
spans 57 Mb (34 cM) on chromosomal region 9p21-
9q12. This region overlaps the three previously reported
FTLD-MND regions on chromosome 9p (Figure 5). The
recombination breakpoint observed in this study at
D9S169 narrows the telomeric boundary of the combined
published minimal disease region by 1.1 Mb.
Conclusion
Frontotemporal lobar degeneration (FTLD) is a clinically,
pathologically and genetically heterogeneous disorder. To
date, at least 22 families with FTLD and/or MND have
now been reported with genetic linkage to chromosome
9p [13-16] providing strong evidence that an additional
FTLD gene exists. In this study we describe a large Austral-
ian FTLD-MND family that shows linkage to the chromo-
some 9p21.1-21.2 locus. With a significant two-point
LOD score of 3.24 and a multi-point LOD score of 3.41,
this is the only study that have provided statistically signif-
icant evidence for linkage from a single pedigree, the other
pedigrees having two-point LOD scores of 2.41 [16], 2.81
[18] and 2.33 [17]. This means that we can rely on our
haplotype analysis with greater statistical certainty. In
addition, the family shows considerable clinical heteroge-
neity, compared to some other families that have been
linked to the same locus.
Diagram of chromosome 9p-linked families with FTLD-MND Figure 5
Diagram of chromosome 9p-linked families with FTLD-MND.BMC Neurology 2008, 8:32 http://www.biomedcentral.com/1471-2377/8/32
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Our genome-wide linkage analysis led to the identifica-
tion of a genetic locus on chromosome 9p21.1-9q21.3.
The resulting 57 Mb disease haplotype region overlaps
with three other FTLD-MND loci identified by Morita et
al., [17] Vance et al., [16] and Valdmanis et al. [18] (Figure
5) providing further evidence for this region as the disease
locus. In combination, the four linkage studies collec-
tively define a likely disease haplotype of 7.0 Mb between
D9S169 and D9S1805 (Figure 5). We note that this hap-
lotype does not overlap with the most recent preliminary
abstract report of a 7.4 cM haplotype on the 9p region by
Yan et al. [31] although, it does overlap with a region that
was originally reported in abstract form by Yan et al. [19]
Given that Yan's latest reported region is probably based
on recombination events drawn from multiple families it
is possible that one of the defining break points may be a
false positive due to the low statistical power of individual
pedigrees, [31] or that a disease haplotype boundary was
defined by a phenocopy as observed in our pedigree. The
region defined by D9S169 and D9S1118 (Figure 4) har-
bours the five transcripts that have been thoroughly
screened in this study and by Momeni et al. [20] with no
plausible mutations having been detected.
Changes in personality and behaviour, motor dysfunction
as well as Ub/TDP-43 positive pathology represent the
core clinical and neuropathological features characteristic
of FTLD-MND families linked to 9p. In this study we
describe an FTLD-MND family with additional clinical
and pathological findings, not previously described in the
chromosome 9p-linked families. Early and severe mem-
ory impairment is generally held to be an exclusion crite-
rion for the clinical diagnosis of FTLD. [1] None of the
other chromosome 9-linked pedigrees have reported
major memory impairment as their primary diagnoses,
although Morita et al. [17] mentioned that memory defi-
cits were detected in three affected individuals in their
pedigree. However this aspect was not reported as their
primary diagnosis as their memory deficits were detected
during neuropsychological tests three years before death.
Moreover, Momeni et al. [20] reported that one of their
patients had additional AD-like pathology, namely dif-
fuse β-amyloid (Aβ) positive plaques in the absence of
neuritic plaques and tangles. We too describe a patient
(III:2) who presented with clinical symptoms typical of
AD and at autopsy not only had indisputable TDP-43 pos-
itive neuronal cytoplasmic inclusions but also had amy-
loid-plaques and neurofibrillary tangles characteristic of
AD (Figure 2). It has been postulated that Apolipoprotein
E (APOE) may play a role in the development of Aβ dep-
osition in FTLD cases [32]. There is no apparent associa-
tion of APOE status with the presence of Aβ deposition in
family 14 as the individual who was homozygous e4/e4
(III:12) had less Aβ deposition than the two individuals
who were heterozygous e3/e4 (III:2 and III:3).
The first reported linkage of a novel FTLD-MND locus to
chromosome 9p was in 2006, although no convincing
candidate genes have yet been identified. The issue of phe-
nocopies and the error of reliance on a single meiotic
recombination events to define minimal disease regions
could be a crucial factor in the failure to identify the dis-
ease gene. The recombination breakpoints reported in the
literature by Morita et al. [17] and Valdmanis et al. [18] are
based on a single recombination event in a single pedi-
gree. Moreover, both of these pedigrees have two-point
LOD scores less than 3. Vance et al. [16], using a pedigree
with a LOD score of 2.4, showed recombination in multi-
ple individuals. However, several of the individuals with
the disease haplotype do not have FTLD-MND, [16] call-
ing into question the relevance of this recombination
breakpoint. Our reported increase in the minimal disease
region should inform the other groups that the chromo-
some 9 locus may be more significantly more telomeric
than predicted by the existing recombination breakpoints.
Moreover, we report the existence of a case with clinical
Alzheimer's disease, and FTLD-U neuropathology, who
shares the disease haplotype. This result highlights the
possibility that the classification of late-onset AD patients
in the other linked pedigrees as sporadic dementia cases
or unaffected may be erroneous, thereby reducing statisti-
cal power, or possibly even excluding pedigrees from link-
age analysis. In summary, multiple families with FTLD-
MND, without mutations in the known dementia genes,
have been linked to chromosome 9p. This strongly sug-
gests that the locus on chromosome 9 play a major role in
pathogenic pathways that lead to FTLD-MND, making it
imperative to identify the causative gene(s).
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